Advanced imaging technologies are uncovering surprising roles for CD8+ T cells—not just in immune defense, but also in supporting tissue repair and regeneration.

Normally, immune cells help fight infection, but the overactivation and targeting of ‘self’ tissues in this autoimmune disease generate deleterious outcomes for patients. The identified monocytes were ...

Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in adults aged 65 and older, similar to already approved shots against ...

FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, May 30, 2025 (GLOBE NEWSWIRE) -- Syncromune ® Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T, an in situ ...

image: Colorectal tumour cells can be targeted using a combination treatment strategy involving in situ vaccination and Checkpoint Blockade Therapy. This dual approach enhances anti-tumour immune ...

Source Reference: Lou E, et al "Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre ...

Archive Immune-Complex Disease Author: Charles L. Christian, M.D. Author Info & Affiliations Published April 17, 1969 N Engl J Med 1969;280: 878 - 884 ...

Your immune system harbors a lifetime’s worth of information about threats it’s encountered — a biological Rolodex of baddies. Often the perpetrators are viruses and bacteria you’ve conquered; others ...

ImmunityBio, Inc., a leading immunotherapy company, today announced the European Medicines Agency has accepted for review and begun assessing the marketing authorization application for ANKTIVA in ...

“These anti-immune complex antibodies have not been studied in very much depth, especially in the context of HIV vaccination,” said Andrew Ward, PhD, professor of integrative structural and ...

News Release 16-Jan-2025 Immune complex shaves stem cells to protect against cancer Peer-Reviewed Publication Weill Cornell Medicine ...

CULVER CITY, Calif., January 15, 2025--ImmunityBio, Inc. (NASDAQ: IBRX) today announced the completion of the submissions of its marketing authorization applications (MAA) for ANKTIVA ...